ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
JADO Reports Clinical Proof Of Concept With Raft Modulator In Atopic Dermatitis
JADO Technologies GmbH, the leading
developer of RAFT intervention therapeutics, announced positive
results from a Phase IIa clinical trial of its lead RAFT modulator TF002
in patients with severe atopic dermatitis. TF002, a topical formulation of
miltefosine, exerts its anti-inflammatory activity via RAFT modulation.
RAFTS are sub-compartments in the lipid membrane of cells that play a role
in the complex physiological processes, such as immune response.
The randomised, double-blind, active (hydrocortisone) controlled, 17
patient study demonstrated that TF002 met its primary endpoint of
significant reduction of inflammation in atopic skin. The
anti-inflammatory effect was measured through a highly significant
improvement in TIS (Three Item Severity) score after three week treatment.
Both TF002 and hydrocortisone achieved an improvement of the TIS score of
more than 1.5 which was defined as being clinical efficacious. This result
correlates to significant anti-inflammatory effects and clinically
relevant efficacy on atopic dermatitis skin. TF002 appeared to have
longer-lasting effects in a 4 weeks follow-on examination and did not
induce skin atrophy compared to hydrocortisone, which was measured as a
secondary outcome. TF002 showed a trend of reducing total number of mast
cells.
"This study demonstrates clinical proof of concept for our lead RAFT
modulator product TF002 and validates the RAFT based novel mode of action.
It encourages us to move ahead with its development. We are now in the
process of reformulating the product so that more of the active and less
irritable compound is available to the outer layers of the skin, an area
where mast cells congregate most. The plan will then be to retest TF002 in
placebo and active controlled studies of diseases such as atopic
dermatitis where mast cell activation plays a key role," Charl van Zyl,
CEO of JADO Technologies stated. "We believe that targeting RAFTS in
allergic diseases could potentially lead to effective new treatments
without the side effects commonly seen with currently available
therapies."
About Atopic Dermatitis
Atopic dermatitis is the most common form of the inflammatory skin
disorder, eczema. Approximately 10-20% of the world's population is
affected by this chronic and relapsing condition which has a severe impact
on quality of life. In many, the condition manifests during childhood,
however more than 50% continues to experience symptoms throughout adult
life. Although the precise cause is unknown, atopic dermatitis appears to
be an abnormal response of the immune system.
About RAFTS
RAFTS are discrete sub-compartments in the lipid membrane of cells that
play a central role in the complex physiological processes, such as immune
response or in many pathological situations. In an infectious disease
event, RAFTS are hijacked by pathogens to gain entry into cells. By
blocking this process, JADO is pursuing the development of novel
therapeutics.
About JADO Technologies
JADO is a leader in the emerging field of RAFT intervention therapeutics.
Representing a paradigm shift in drug development, RAFT therapeutics have
the potential to address multiple unmet needs, particularly in allergy,
infectious diseases, Alzheimer's disease and cancer.
RAFTS are sub-compartments of cell membranes that play an integral role in
key biological pathways. The Company's RAFT Intervention Technology®
provides a unique platform, protected by a strong patent position, to
drive significant pipeline development opportunities. JADO has leveraged
its technology to generate multiple small molecule drug candidates, with
its lead program in Phase IIa clinical trials for allergy indications. The
Company is supported by a global network of clinical and academic experts,
including JADO founders, Prof. Kai Simons, Prof. Marino Zerial, Dr.
Teymuras Kurzchalia (Max-Planck Institute of Molecular Cell Biology and
Genetics, Dresden) and Prof. Hans-Joachim Knölker (Technical University of
Dresden). JADO is headquartered in Dresden, Germany with a subsidiary in
Bethlehem, Pennsylvania (USA).
JADO Technologies
JADO rapoarte clinice, dovada de concept cu pluta modulator în atopic dermatitã - JADO Reports Clinical Proof Of Concept With Raft Modulator In Atopic Dermatitis - articole medicale engleza - startsanatate